Tesamorelin
Tesamorelin is a protein pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against growth hormone-releasing hormone receptor.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| urogenital diseases | D000091642 |
| skin and connective tissue diseases | D017437 |
| nutritional and metabolic diseases | D009750 |
| immune system diseases | D007154 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| egrifta sv | Biologic Licensing Application | 2020-04-07 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| hiv-associated lipodystrophy syndrome | EFO_1001348 | D039682 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
38 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Asthma | D001249 | EFO_0000270 | J45 | — | 1 | 12 | 1 | — | 13 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | — | — | 2 | 1 | — | 3 |
| Fetal version | D014710 | — | 1 | 1 | 1 | — | 2 | ||
| Heart failure | D006333 | EFO_0003144 | I50 | — | — | — | 1 | 1 | 2 |
| Labor pain | D048949 | — | — | — | 1 | — | 1 | ||
| Status asthmaticus | D013224 | — | — | — | 1 | — | 1 |
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Thrombocytopenic purpura idiopathic | D016553 | EFO_0007160 | D69.3 | — | 2 | — | — | — | 2 |
| Exercise-induced asthma | D001250 | J45.990 | — | 1 | — | — | — | 1 | |
| Neuralgia | D009437 | EFO_0009430 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | 1 | — | — | — | 1 | 2 |
| Healthy volunteers/patients | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Fetal distress | D005316 | — | — | — | — | 2 | 2 | ||
| Assisted reproductive techniques | D027724 | — | — | — | — | 1 | 1 | ||
| Drug-related side effects and adverse reactions | D064420 | T88.7 | — | — | — | — | 1 | 1 | |
| Meningomyelocele | D008591 | EFO_1001369 | Q05 | — | — | — | — | 1 | 1 |
| Hypertrophy | D006984 | EFO_0002460 | — | — | — | — | 1 | 1 | |
| Exercise | D015444 | EFO_0000483 | — | — | — | — | 1 | 1 | |
| Fatigue | D005221 | HP_0012378 | R53.83 | — | — | — | — | 1 | 1 |
| Hydrogen-ion concentration | D006863 | — | — | — | — | 1 | 1 | ||
| Hot flashes | D019584 | — | — | — | — | 1 | 1 | ||
| Menopause | D008593 | EFO_0003922 | N95 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | TESAMORELIN |
| INN | tesamorelin |
| Description | Tesamorelin (INN) (trade name Egrifta) is a synthetic form of growth-hormone-releasing hormone (GHRH) which is used in the treatment of HIV-associated lipodystrophy, approved initially in 2010. It is produced and developed by Theratechnologies, Inc. of Canada. The drug is a synthetic peptide consisting of all 44 amino acids of human GHRH with the addition of a trans-3-hexenoic acid group.
|
| Classification | Peptide |
| Drug class | prehormones or hormone-release stimulating peptides: growth hormone-release stimulating peptides |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 218949-48-5 |
| RxCUI | 1044584 |
| ChEMBL ID | CHEMBL1237026 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB08869 |
| UNII ID | MQG94M5EEO (ChemIDplus, GSRS) |
Target
Agency Approved
GHRHR
GHRHR
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 201 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,658 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more